http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 15 Jun 2026 06:13:15 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Equity+Offerings/Decoy+Therapeutics+%28DCOY%29+files+for+808K+share+offering+by+selling+stockholders/26643665.html <p>Decoy Therapeutics (NASDAQ: DCOY) has filed for up to 808,000 share offering by selling stockholders.</p> http://www.streetinsider.com/Equity+Offerings/Decoy+Therapeutics+%28DCOY%29+files+for+808K+share+offering+by+selling+stockholders/26643665.html Mon, 15 Jun 2026 06:13:15 -0400 DCOY http://www.streetinsider.com/Corporate+News/Decoy+Therapeutics+%28DCOY%29+files+for+808K+share+offering+by+selling+stockholders/26643665.html <p>Decoy Therapeutics (NASDAQ: DCOY) has filed for up to 808,000 share offering by selling stockholders.</p> http://www.streetinsider.com/Corporate+News/Decoy+Therapeutics+%28DCOY%29+files+for+808K+share+offering+by+selling+stockholders/26643665.html Mon, 15 Jun 2026 06:13:15 -0400 DCOY http://www.streetinsider.com/SEC+Filings/Form++S-1++++++++Decoy+Therapeutics+Inc.++++++++++++++/26643646.html si-local-file:///var/storage/secattach/20260615/26643646.html http://www.streetinsider.com/SEC+Filings/Form++S-1++++++++Decoy+Therapeutics+Inc.++++++++++++++/26643646.html Mon, 15 Jun 2026 06:06:00 -0400 DCOY O.22255725 http://www.streetinsider.com/SEC+Filings/Form++S-1++++++++Decoy+Therapeutics+Inc.++++++++++++++/26643646.html si-local-file:///var/storage/secattach/20260615/26643646.html http://www.streetinsider.com/SEC+Filings/Form++S-1++++++++Decoy+Therapeutics+Inc.++++++++++++++/26643646.html Mon, 15 Jun 2026 06:06:00 -0400 DCOY O.22255725 http://www.streetinsider.com/Press+Releases/Decoy+Therapeutics%27+CEO+to+Participate+in+hVIVO+Capital+Markets+Day+in+London/26614523.html <div class="xn-content"> <p class="prntac"><i><person>Rick Pierce</person> to join speakers from <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>, <span>RA Capital</span> and <span value="ACORN:0984555587" idsrc="xmltag.org" >ILiAD Biotechnologies</span> for discussion on early clinical development </i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced that Chief Executive Officer <person>Rick Pierce</person> will speak at the Capital Markets Day hosted by hVIVO plc (AIM: HVO) on <chron>June 11, 2026</chron> in <location>Canary Wharf</location>, <location value="LU/gb.eng.london" idsrc="xmltag.org" >London</location>.</p> http://www.streetinsider.com/Press+Releases/Decoy+Therapeutics%27+CEO+to+Participate+in+hVIVO+Capital+Markets+Day+in+London/26614523.html Mon, 08 Jun 2026 08:00:00 -0400 A.09845555 A.31197700 DCOY HVO O.00831659 O.22255725 O.40295562 http://www.streetinsider.com/Press+Releases/Decoy+Therapeutics%27+CEO+to+Participate+in+hVIVO+Capital+Markets+Day+in+London/26614523.html <div class="xn-content"> <p class="prntac"><i><person>Rick Pierce</person> to join speakers from <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>, <span>RA Capital</span> and <span value="ACORN:0984555587" idsrc="xmltag.org" >ILiAD Biotechnologies</span> for discussion on early clinical development </i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced that Chief Executive Officer <person>Rick Pierce</person> will speak at the Capital Markets Day hosted by hVIVO plc (AIM: HVO) on <chron>June 11, 2026</chron> in <location>Canary Wharf</location>, <location value="LU/gb.eng.london" idsrc="xmltag.org" >London</location>.</p> http://www.streetinsider.com/Press+Releases/Decoy+Therapeutics%27+CEO+to+Participate+in+hVIVO+Capital+Markets+Day+in+London/26614523.html Mon, 08 Jun 2026 08:00:00 -0400 A.09845555 A.31197700 DCOY HVO O.00831659 O.22255725 O.40295562 http://www.streetinsider.com/Press+Releases/Decoy+Therapeutics%27+CEO+to+Participate+in+hVIVO+Capital+Markets+Day+in+London/26614523.html <div class="xn-content"> <p class="prntac"><i><person>Rick Pierce</person> to join speakers from <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>, <span>RA Capital</span> and <span value="ACORN:0984555587" idsrc="xmltag.org" >ILiAD Biotechnologies</span> for discussion on early clinical development </i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced that Chief Executive Officer <person>Rick Pierce</person> will speak at the Capital Markets Day hosted by hVIVO plc (AIM: HVO) on <chron>June 11, 2026</chron> in <location>Canary Wharf</location>, <location value="LU/gb.eng.london" idsrc="xmltag.org" >London</location>.</p> http://www.streetinsider.com/Press+Releases/Decoy+Therapeutics%27+CEO+to+Participate+in+hVIVO+Capital+Markets+Day+in+London/26614523.html Mon, 08 Jun 2026 08:00:00 -0400 A.09845555 A.31197700 DCOY HVO O.00831659 O.22255725 O.40295562 http://www.streetinsider.com/Press+Releases/Decoy+Therapeutics%27+CEO+to+Participate+in+hVIVO+Capital+Markets+Day+in+London/26614523.html <div class="xn-content"> <p class="prntac"><i><person>Rick Pierce</person> to join speakers from <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>, <span>RA Capital</span> and <span value="ACORN:0984555587" idsrc="xmltag.org" >ILiAD Biotechnologies</span> for discussion on early clinical development </i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced that Chief Executive Officer <person>Rick Pierce</person> will speak at the Capital Markets Day hosted by hVIVO plc (AIM: HVO) on <chron>June 11, 2026</chron> in <location>Canary Wharf</location>, <location value="LU/gb.eng.london" idsrc="xmltag.org" >London</location>.</p> http://www.streetinsider.com/Press+Releases/Decoy+Therapeutics%27+CEO+to+Participate+in+hVIVO+Capital+Markets+Day+in+London/26614523.html Mon, 08 Jun 2026 08:00:00 -0400 A.09845555 A.31197700 DCOY HVO O.00831659 O.22255725 O.40295562 http://www.streetinsider.com/Press+Releases/Decoy+Therapeutics%27+CEO+to+Participate+in+hVIVO+Capital+Markets+Day+in+London/26614523.html <div class="xn-content"> <p class="prntac"><i><person>Rick Pierce</person> to join speakers from <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>, <span>RA Capital</span> and <span value="ACORN:0984555587" idsrc="xmltag.org" >ILiAD Biotechnologies</span> for discussion on early clinical development </i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced that Chief Executive Officer <person>Rick Pierce</person> will speak at the Capital Markets Day hosted by hVIVO plc (AIM: HVO) on <chron>June 11, 2026</chron> in <location>Canary Wharf</location>, <location value="LU/gb.eng.london" idsrc="xmltag.org" >London</location>.</p> http://www.streetinsider.com/Press+Releases/Decoy+Therapeutics%27+CEO+to+Participate+in+hVIVO+Capital+Markets+Day+in+London/26614523.html Mon, 08 Jun 2026 08:00:00 -0400 A.09845555 A.31197700 DCOY HVO O.00831659 O.22255725 O.40295562 http://www.streetinsider.com/Press+Releases/Decoy+Therapeutics%27+CEO+to+Participate+in+hVIVO+Capital+Markets+Day+in+London/26614523.html <div class="xn-content"> <p class="prntac"><i><person>Rick Pierce</person> to join speakers from <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>, <span>RA Capital</span> and <span value="ACORN:0984555587" idsrc="xmltag.org" >ILiAD Biotechnologies</span> for discussion on early clinical development </i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced that Chief Executive Officer <person>Rick Pierce</person> will speak at the Capital Markets Day hosted by hVIVO plc (AIM: HVO) on <chron>June 11, 2026</chron> in <location>Canary Wharf</location>, <location value="LU/gb.eng.london" idsrc="xmltag.org" >London</location>.</p> http://www.streetinsider.com/Press+Releases/Decoy+Therapeutics%27+CEO+to+Participate+in+hVIVO+Capital+Markets+Day+in+London/26614523.html Mon, 08 Jun 2026 08:00:00 -0400 A.09845555 A.31197700 DCOY HVO O.00831659 O.22255725 O.40295562 http://www.streetinsider.com/Press+Releases/Decoy+Therapeutics%27+CEO+to+Participate+in+hVIVO+Capital+Markets+Day+in+London/26614523.html <div class="xn-content"> <p class="prntac"><i><person>Rick Pierce</person> to join speakers from <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>, <span>RA Capital</span> and <span value="ACORN:0984555587" idsrc="xmltag.org" >ILiAD Biotechnologies</span> for discussion on early clinical development </i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced that Chief Executive Officer <person>Rick Pierce</person> will speak at the Capital Markets Day hosted by hVIVO plc (AIM: HVO) on <chron>June 11, 2026</chron> in <location>Canary Wharf</location>, <location value="LU/gb.eng.london" idsrc="xmltag.org" >London</location>.</p> http://www.streetinsider.com/Press+Releases/Decoy+Therapeutics%27+CEO+to+Participate+in+hVIVO+Capital+Markets+Day+in+London/26614523.html Mon, 08 Jun 2026 08:00:00 -0400 A.09845555 A.31197700 DCOY HVO O.00831659 O.22255725 O.40295562 http://www.streetinsider.com/PRNewswire/Decoy+Therapeutics%27+CEO+to+Participate+in+hVIVO+Capital+Markets+Day+in+London/26614523.html <div class="xn-content"> <p class="prntac"><i><person>Rick Pierce</person> to join speakers from <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>, <span>RA Capital</span> and <span value="ACORN:0984555587" idsrc="xmltag.org" >ILiAD Biotechnologies</span> for discussion on early clinical development </i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced that Chief Executive Officer <person>Rick Pierce</person> will speak at the Capital Markets Day hosted by hVIVO plc (AIM: HVO) on <chron>June 11, 2026</chron> in <location>Canary Wharf</location>, <location value="LU/gb.eng.london" idsrc="xmltag.org" >London</location>.</p> http://www.streetinsider.com/PRNewswire/Decoy+Therapeutics%27+CEO+to+Participate+in+hVIVO+Capital+Markets+Day+in+London/26614523.html Mon, 08 Jun 2026 08:00:00 -0400 A.09845555 A.31197700 DCOY HVO O.00831659 O.22255725 O.40295562 http://www.streetinsider.com/PRNewswire/Decoy+Therapeutics%27+CEO+to+Participate+in+hVIVO+Capital+Markets+Day+in+London/26614523.html <div class="xn-content"> <p class="prntac"><i><person>Rick Pierce</person> to join speakers from <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>, <span>RA Capital</span> and <span value="ACORN:0984555587" idsrc="xmltag.org" >ILiAD Biotechnologies</span> for discussion on early clinical development </i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced that Chief Executive Officer <person>Rick Pierce</person> will speak at the Capital Markets Day hosted by hVIVO plc (AIM: HVO) on <chron>June 11, 2026</chron> in <location>Canary Wharf</location>, <location value="LU/gb.eng.london" idsrc="xmltag.org" >London</location>.</p> http://www.streetinsider.com/PRNewswire/Decoy+Therapeutics%27+CEO+to+Participate+in+hVIVO+Capital+Markets+Day+in+London/26614523.html Mon, 08 Jun 2026 08:00:00 -0400 A.09845555 A.31197700 DCOY HVO O.00831659 O.22255725 O.40295562 http://www.streetinsider.com/PRNewswire/Decoy+Therapeutics%27+CEO+to+Participate+in+hVIVO+Capital+Markets+Day+in+London/26614523.html <div class="xn-content"> <p class="prntac"><i><person>Rick Pierce</person> to join speakers from <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>, <span>RA Capital</span> and <span value="ACORN:0984555587" idsrc="xmltag.org" >ILiAD Biotechnologies</span> for discussion on early clinical development </i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced that Chief Executive Officer <person>Rick Pierce</person> will speak at the Capital Markets Day hosted by hVIVO plc (AIM: HVO) on <chron>June 11, 2026</chron> in <location>Canary Wharf</location>, <location value="LU/gb.eng.london" idsrc="xmltag.org" >London</location>.</p> http://www.streetinsider.com/PRNewswire/Decoy+Therapeutics%27+CEO+to+Participate+in+hVIVO+Capital+Markets+Day+in+London/26614523.html Mon, 08 Jun 2026 08:00:00 -0400 A.09845555 A.31197700 DCOY HVO O.00831659 O.22255725 O.40295562 http://www.streetinsider.com/PRNewswire/Decoy+Therapeutics%27+CEO+to+Participate+in+hVIVO+Capital+Markets+Day+in+London/26614523.html <div class="xn-content"> <p class="prntac"><i><person>Rick Pierce</person> to join speakers from <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>, <span>RA Capital</span> and <span value="ACORN:0984555587" idsrc="xmltag.org" >ILiAD Biotechnologies</span> for discussion on early clinical development </i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced that Chief Executive Officer <person>Rick Pierce</person> will speak at the Capital Markets Day hosted by hVIVO plc (AIM: HVO) on <chron>June 11, 2026</chron> in <location>Canary Wharf</location>, <location value="LU/gb.eng.london" idsrc="xmltag.org" >London</location>.</p> http://www.streetinsider.com/PRNewswire/Decoy+Therapeutics%27+CEO+to+Participate+in+hVIVO+Capital+Markets+Day+in+London/26614523.html Mon, 08 Jun 2026 08:00:00 -0400 A.09845555 A.31197700 DCOY HVO O.00831659 O.22255725 O.40295562 http://www.streetinsider.com/PRNewswire/Decoy+Therapeutics%27+CEO+to+Participate+in+hVIVO+Capital+Markets+Day+in+London/26614523.html <div class="xn-content"> <p class="prntac"><i><person>Rick Pierce</person> to join speakers from <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>, <span>RA Capital</span> and <span value="ACORN:0984555587" idsrc="xmltag.org" >ILiAD Biotechnologies</span> for discussion on early clinical development </i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced that Chief Executive Officer <person>Rick Pierce</person> will speak at the Capital Markets Day hosted by hVIVO plc (AIM: HVO) on <chron>June 11, 2026</chron> in <location>Canary Wharf</location>, <location value="LU/gb.eng.london" idsrc="xmltag.org" >London</location>.</p> http://www.streetinsider.com/PRNewswire/Decoy+Therapeutics%27+CEO+to+Participate+in+hVIVO+Capital+Markets+Day+in+London/26614523.html Mon, 08 Jun 2026 08:00:00 -0400 A.09845555 A.31197700 DCOY HVO O.00831659 O.22255725 O.40295562 http://www.streetinsider.com/PRNewswire/Decoy+Therapeutics%27+CEO+to+Participate+in+hVIVO+Capital+Markets+Day+in+London/26614523.html <div class="xn-content"> <p class="prntac"><i><person>Rick Pierce</person> to join speakers from <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>, <span>RA Capital</span> and <span value="ACORN:0984555587" idsrc="xmltag.org" >ILiAD Biotechnologies</span> for discussion on early clinical development </i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced that Chief Executive Officer <person>Rick Pierce</person> will speak at the Capital Markets Day hosted by hVIVO plc (AIM: HVO) on <chron>June 11, 2026</chron> in <location>Canary Wharf</location>, <location value="LU/gb.eng.london" idsrc="xmltag.org" >London</location>.</p> http://www.streetinsider.com/PRNewswire/Decoy+Therapeutics%27+CEO+to+Participate+in+hVIVO+Capital+Markets+Day+in+London/26614523.html Mon, 08 Jun 2026 08:00:00 -0400 A.09845555 A.31197700 DCOY HVO O.00831659 O.22255725 O.40295562 http://www.streetinsider.com/PRNewswire/Decoy+Therapeutics%27+CEO+to+Participate+in+hVIVO+Capital+Markets+Day+in+London/26614523.html <div class="xn-content"> <p class="prntac"><i><person>Rick Pierce</person> to join speakers from <span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>, <span>RA Capital</span> and <span value="ACORN:0984555587" idsrc="xmltag.org" >ILiAD Biotechnologies</span> for discussion on early clinical development </i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced that Chief Executive Officer <person>Rick Pierce</person> will speak at the Capital Markets Day hosted by hVIVO plc (AIM: HVO) on <chron>June 11, 2026</chron> in <location>Canary Wharf</location>, <location value="LU/gb.eng.london" idsrc="xmltag.org" >London</location>.</p> http://www.streetinsider.com/PRNewswire/Decoy+Therapeutics%27+CEO+to+Participate+in+hVIVO+Capital+Markets+Day+in+London/26614523.html Mon, 08 Jun 2026 08:00:00 -0400 A.09845555 A.31197700 DCOY HVO O.00831659 O.22255725 O.40295562 http://www.streetinsider.com/SEC+Filings/Form++RW+++++++++Decoy+Therapeutics+Inc.++++++++++++++/26611627.html si-local-file:///var/storage/secattach/20260605/26611627.html http://www.streetinsider.com/SEC+Filings/Form++RW+++++++++Decoy+Therapeutics+Inc.++++++++++++++/26611627.html Fri, 05 Jun 2026 16:33:00 -0400 DCOY O.22255725 http://www.streetinsider.com/SEC+Filings/Form++RW+++++++++Decoy+Therapeutics+Inc.++++++++++++++/26611627.html si-local-file:///var/storage/secattach/20260605/26611627.html http://www.streetinsider.com/SEC+Filings/Form++RW+++++++++Decoy+Therapeutics+Inc.++++++++++++++/26611627.html Fri, 05 Jun 2026 16:33:00 -0400 DCOY O.22255725 http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Decoy+Therapeutics+Inc.++++++++++++++/26602942.html si-local-file:///var/storage/secattach/20260604/26602942.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Decoy+Therapeutics+Inc.++++++++++++++/26602942.html Thu, 04 Jun 2026 08:30:00 -0400 DCOY O.22255725 http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Decoy+Therapeutics+Inc.++++++++++++++/26602942.html si-local-file:///var/storage/secattach/20260604/26602942.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Decoy+Therapeutics+Inc.++++++++++++++/26602942.html Thu, 04 Jun 2026 08:30:00 -0400 DCOY O.22255725 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Decoy+Therapeutics+Inc.+++For%3A+Jun+04/26602886.html si-local-file:///var/storage/secattach/20260604/26602886.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Decoy+Therapeutics+Inc.+++For%3A+Jun+04/26602886.html Thu, 04 Jun 2026 08:27:00 -0400 DCOY O.22255725 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Decoy+Therapeutics+Inc.+++For%3A+Jun+04/26602886.html si-local-file:///var/storage/secattach/20260604/26602886.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Decoy+Therapeutics+Inc.+++For%3A+Jun+04/26602886.html Thu, 04 Jun 2026 08:27:00 -0400 DCOY O.22255725 http://www.streetinsider.com/Board+Changes/Decoy+Therapeutics+nominates+Patricia+Gauthier+for+board+election/26595712.html <p>Decoy Therapeutics Inc. (NASDAQ: DCOY) announced the nomination of Patricia Gauthier as a Class II director for election at the company's annual stockholders meeting on July 14, 2026.</p> <p>Gauthier currently serves as Senior Vice President and Regional Head for Australia, Canada and the United Kingdom at Moderna, a position she has held since 2025. In this role, she leads strategy and operations across biomanufacturing, national health security partnerships and commercialization for approximately 500 employees.</p> <p>Prior to her current position, Gauthier served as General Manager of Moderna Canada, where she built the affiliate from inception and supported delivery of more than 50 million http://www.streetinsider.com/Board+Changes/Decoy+Therapeutics+nominates+Patricia+Gauthier+for+board+election/26595712.html Wed, 03 Jun 2026 08:01:12 -0400 A.26182308 DCOY O.03301479 O.22255725